Last updated on November 2019

Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.

Brief description of study

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies.

Part 1 of the study is monotherapy dose escalation. Part 2 of the study is monotherapy expansion groups for relapsed/refractory chronic lymphocytic leukaemia (CLL), AML/ myelodysplastic syndromes (MDS), and multiple myeloma (MM) Part 3 is a sequential, dose-escalation study of the combination of AZD5991 and venetoclax in subjects with relapsed/refractory AML/MDS

Clinical Study Identifier: NCT03218683

Find a site near you

Start Over

Research Site

Washington, WA United States
  Connect »